Background Azithromycin mass drug administration (MDA) to ages 1–59 months can reduce childhood mortality; however, more ...
Immuneering Corporation stays a Strong Buy: pancreatic cancer combo shows 64% 12‑mo OS, strong safety, and clear catalysts ...
MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback